NESS ZIONA, Israel--(BUSINESS WIRE)--Atox Bio today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for AB103 for the treatment of necrotizing soft tissue infections.
Necrotizing soft tissue infections (NSTI) includes several distinctive clinical diagnoses that share clinical features representing the most severe types of infections involving the skin, skin structures and soft tissue and having a high mortality rate. Currently, there are no approved treatments for NSTI. The current principles of management include early diagnosis with prompt and repeated surgical debridement, aggressive resuscitation and physiologic support, in addition to antimicrobial drugs.
Necrotizing soft tissue infections (NSTI) includes several distinctive clinical diagnoses that share clinical features representing the most severe types of infections involving the skin, skin structures and soft tissue and having a high mortality rate. Currently, there are no approved treatments for NSTI. The current principles of management include early diagnosis with prompt and repeated surgical debridement, aggressive resuscitation and physiologic support, in addition to antimicrobial drugs.
